PHAR-MOR CLOSING 58 STORES AS PART OF REVISED BUSINESS PLAN to be presented to creditors in early May, Phar-Mor reported April 16. Eight additional stores may close pending the outcome of negotiations with the landlords, the company said. Phar-Mor's revised business plan will include "completion of its store consolidation program, reorganization of its corporate overhead and distribution functions, investment in information and distribution technology, and improvements in its merchandising and marketing approach," Phar-Mor outlined. The Youngstown, Ohio-based deep discount retail chain expects the most recently announced closings to be its last. Including the 58 definite closings, Phar-Mor has shut down a total of 144 stores since filing for Chapter 11 in August after uncovering a fraud and embezzlement scheme by previous management. A total of 166 "established, geographically-concentrated, profitable deep discount drug stores" will remain after the upcoming shut-downs, the company said. The closings are expected to reduce Phar-Mor's corporate overhead and distribution costs by approximately 30%, the company reported. The downsizing will affect approximately 522 corporate, distribution and field support personnel as well as 3,600 full- and part-time employees. Phar-Mor based its decision to close stores on profitability, growth potential, strength of market position, location and performance. The stores will continue normal operations until bankruptcy court approves closings, at which time they will begin "Going Out of Business" sales. A hearing before the bankruptcy court is scheduled for May 4. Since filing for bankruptcy, Phar-Mor has increased liquidity to about $ 208 mil. in cash as of April 14 from approximately $ 50 mil. in August. Additional progress noted by the company includes setting up a $ 150 mil. credit facility, maintaining a "normal" flow of goods, reducing operating losses and changing top management to include Chairman David Shapira, CEO Antonio Alvarez and President and Chief Operating Officer David Schwartz.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Sponsors can expect faster evaluation processes for key medicines and greater support in mitigating medicines supply shortages this year as part of the European Medicines Agency’s digital transformation overhaul.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
By stepping into the role of the Centers for Disease Control and Advisory Committee on Immunization Practices, HHS Secretary Robert F. Kennedy Jr. is causing further confusion and uncertainty about vaccine policy, experts say.
